Related Experiment Video
Updated: Aug 11, 2026
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Hyponatremia and heart failure--treatment considerations
1Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-0160, USA. dsica@hsc.vcu.edu
Congestive Heart Failure (Greenwich, Conn.)
|February 14, 2006
Summary
Hyponatremia in heart failure patients is complex and linked to disease severity. New vasopressin receptor antagonists offer a safer, effective treatment for this condition, potentially improving outcomes.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hyponatremia is common in heart failure patients, correlating with disease severity and poor outcomes.
- Traditional treatments include improving cardiac function, fluid restriction, and limited use of agents like hypertonic saline, diuretics, lithium, or demeclocycline.
- Older therapies carry risks of renal and cardiovascular side effects due to their mechanism of action on vasopressin.
Purpose of the Study:
- To review the multifactorial nature of hyponatremia in heart failure.
- To evaluate traditional and novel therapeutic approaches.
- To highlight the potential of vasopressin receptor antagonists in managing heart failure-related hyponatremia.
Main Methods:
- Literature review of hyponatremia in heart failure.
- Analysis of traditional treatment strategies and their limitations.
- Examination of the mechanism and efficacy of vasopressin receptor antagonists.
Main Results:
- Hyponatremia in heart failure is multifactorial and prognostically significant.
- Established treatments have limitations and potential adverse effects.
- Vasopressin receptor antagonists (e.g., conivaptan, lixivaptan, tolvaptan) increase free water excretion safely.
- These agents offer a targeted approach without the side effects of older therapies.
Conclusions:
- Vasopressin receptor antagonists represent a significant advancement in treating heart failure-related hyponatremia.
- These aquaretic drugs provide a safer alternative to traditional therapies.
- They may become essential adjuncts to diuretics in diuretic-resistant heart failure patients.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...